QUILT-3.032
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
- NCT03022825 ↗
- Active, not recruiting
- ImmunityBio, Inc.
- Deep
We haven't built an HCP commentary report on QUILT-3.032 (nogapendekin alfa inbakicept (N-803) plus BCG in BCG-unresponsive high-grade non-muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 21 newest of 33 indexed sources (Jul 2019 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether treatment provides benefit beyond the natural history of disease
- Whether papillary-only efficacy can be inferred from data including CIS
- Whether outcomes can be compared reliably across bladder cancer treatments
Also discussed: bladder preservation, IL-15 immune activation, treatment tolerability.
Indexed commentary on QUILT-3.032 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 19 | |
| Podcasts | 7 | |
| YouTube | 4 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- N-803 and BCG; N-803
- Arms
- BCG+N-803 · Experimental
- Enrollment
- 190
- Primary outcomes
- Complete Response
- Disease-Free Rate
- Sponsor
- ImmunityBio, Inc.
- Start
- Jun 2, 2017
- Primary completion
- Oct 1, 2024
- Results posted
- No
- Registry record
- NCT03022825 · updated Oct 16, 2025
Publications
linked from the registry- Chang SS, Chamie K, Kramolowsky E, Gonzalgo ML, Agarwal PK, Bassett JC, Bjurlin M, Cher ML, Clark W, Cowan BE, David R, Goldfischer E, Guru K, Jalkut MW, Kaffenberger SD, Kaminetsky J, Corcoran A, Koo AS, Sexton WJ, Tikhonenkov SN, Shah MS, Trabulsi EJ, Trainer AF, Spilman P, Huang M, Bhar P, Drusbosky LM, Sender L, Brown B, Reddy S, Soon-Shiong P. Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer. J Urol. 2026 Jan;215(1):44-56. doi: 10.1097/JU.0000000000004782. Epub 2025 Sep 16. PubMed 40956664
- Chamie K, Chang SS, Rosser CJ, Kramolowski E, Gonzalgo ML, Sexton WJ, Spilman P, Sender L, Reddy S, Soon-Shiong P. N-803 Plus BCG Treatment for BCG-Naive or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review. Future Oncol. 2024;20(31):2307-2317. doi: 10.1080/14796694.2024.2363744. Epub 2024 Jul 2. PubMed 38953850